UnitedHealth Group is demonstrating a solid recovery with its Medical Cost Ratio (MCR) improving from 89.4% to 86.7%, and its earnings per share (EPS) guidance for 2026 has been raised twice. The company is strategically shedding lower-quality membership to enhance margins, while its operating cash flow guidance has increased from over $18 billion to about $24 billion. The healthcare sector overall looks promising, especially as it lags behind the S&P 500 and benefits from a more defensive economic environment. At a valuation of roughly 18.7 times 2026 EPS, UnitedHealth appears undervalued relative to management's long-term EPS growth target of 13%-16%.
UnitedHealth Group shares are trading at USD 376.99 on Pluang as of Sep 19, 2026 04:21 WIB, showing a modest 0.47% gain in the past day. Despite strong fundamentals, Pluang order activity heavily favors selling, with 97% of orders to sell versus 3% to buy. The stock's dividend yield stands at 2.47%, reflecting a steady income component for investors.
